Logo
x

Search

Subscribe Now

Symptomatic

BMS Reports the US FDA's Acceptance of NDA for Mavacamten to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

BMS Reports the US FDA's Acceptance of NDA for Mavacamten to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

  • March 22, 2021
Eli Lilly Collaborates with GSK and VIR to Evaluate Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

Eli Lilly Collaborates with GSK and VIR to Evaluate Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

  • January 28, 2021
MyoKardia's Mavacamten Receives the US FDA's Breakthrough Therapy Designation for Symptomatic Patients with Obstructive Hypertrophic Cardiomyopathy

MyoKardia's Mavacamten Receives the US FDA's Breakthrough Therapy Designation for Symptomatic Patients with Obstructive Hypertroph...

  • July 23, 2020
Merck and Bayer Receive the US FDA's Priority Review for Vericiguat to Reduce the Risk of CV Death in Patients with Symptomatic Chronic Heart Failure with HFrEF

Merck and Bayer Receive the US FDA's Priority Review for Vericiguat to Reduce the Risk of CV Death in Patients with Symptomatic Ch...

  • July 16, 2020
Pfizer's Fragmin (dalteparin sodium) Receives FDA's Approval for Symptomatic Venous Thromboembolism in Pediatric Patients

Pfizer's Fragmin (dalteparin sodium) Receives FDA's Approval for Symptomatic Venous Thromboembolism in Pediatric Patients

  • May 17, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.